NCT04335916

Brief Summary

The aim of this study is to identify specifics of pre-ECT assessments and ECT application in European psychiatric services. We will engage European centres that provide ECT for psychiatric patients and for psychiatric indications. It could bring better insights on current standards and possibly give some further improvements in the field of European ECT practices.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2020

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

April 3, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 7, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

April 7, 2020

Status Verified

April 1, 2020

Enrollment Period

5 months

First QC Date

April 3, 2020

Last Update Submit

April 3, 2020

Conditions

Keywords

Electroconvulsive therapyPre-ECT evaluation

Outcome Measures

Primary Outcomes (2)

  • pre-ECT evaluation data

    Data on pre-ECT evaluation collected with specially designed survey for this research. Pre-ECT evaluation treatment includes are there written or agreed indications, inclusion and exclusion criteria and pre-ECT evaluation, the common neuropsychiatric and somatic evaluation for ECT candidate.

    Baseline

  • ECT administration data

    Data on ECT application collected with specially designed survey for this research. The survey examines the most common methods of applying ECT, provided education and the necessary legal and ethical codes.

    Baseline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Departments that provide pre-ECT assessment, ECT application or both in Europe

You may qualify if:

  • departments that provide pre-ECT assessment
  • departments that provide ECT application
  • departments that provide both pre-ECT assessment and ECT application

You may not qualify if:

  • departments that used to provide either pre-ECT assessment or ECT application
  • departments that refer patients for ECT but don't provide pre-ECT assessment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Klinički Bolnički Centar Zagreb

Zagreb, City of Zagreb, 10000, Croatia

RECRUITING

Related Publications (1)

  • Medved S, Zaja N, Gazdag G, Lengvenyte A, Morkl S, Mucci F, Ristic I, Jerotic S, Regente JF, Ivanovic I, Purisic A, Sasvary F, Sivasanker V, Ziblak A, Lookene M, Sienaert P, Szczegielniak A, Trancik P, Becirovic E, Koutsomitros T, Grech G, Tapoi C, Radmanovic B, Strohle A, Bajs Janovic M, Sartorius N. Preliminary Assessment of Pre-Electroconvulsive Therapy Evaluation Practices in European Countries: The Need for Guidelines. J ECT. 2022 Dec 1;38(4):230-237. doi: 10.1097/YCT.0000000000000854. Epub 2022 Apr 23.

MeSH Terms

Conditions

DepressionCatatoniaSchizophreniaPsychotic DisordersNeuroleptic Malignant Syndrome

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsSchizophrenia Spectrum and Other Psychotic DisordersMental DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNeurotoxicity SyndromesPoisoningChemically-Induced Disorders

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 3, 2020

First Posted

April 7, 2020

Study Start

April 1, 2020

Primary Completion

September 1, 2020

Study Completion

November 1, 2020

Last Updated

April 7, 2020

Record last verified: 2020-04

Locations